LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: The effect of rifampicin on the neuronal cell survival in prımary cortical neuron culture after laser axotomy

    Mehmet Ozansoy / Ebru Coşkun / Muzaffer Beyza Çeti̇n Ozansoy / Şeyda Çankaya / Mehmet Yalçın Günal / Zübeyir Bayraktaroğlu / Burak Yuluğ / Lütfü Hanoğlu

    Acta Medica Alanya, Vol 3, Iss 2, Pp 135-

    2019  Volume 140

    Abstract: Aim: Neurodegeneration caused by the axonal injury is a widely seen phenomenon in spinal cord and traumatic brain injuries. Due to the disintegration of the synaptic connection neurotrophic factors could not be transported retrogradely towards the cell ... ...

    Abstract Aim: Neurodegeneration caused by the axonal injury is a widely seen phenomenon in spinal cord and traumatic brain injuries. Due to the disintegration of the synaptic connection neurotrophic factors could not be transported retrogradely towards the cell body and the deprivation of the trophic factors lead to the degeneration and death of the injured neuron. Rifampicin is an antibiotic exhibiting several neuroprotective functions in various neurodegenerative conditions. Here we aim to investigate the acute neuroprotective effect of rifampicin in primary cortical neuron culture in which neurons are axotomized by laser axotomy.Methods: Neonatal male mice were used in order to isolate cortical neurons. Isolated primary cortical neurons were cultured. After 24 hours three different rifampicin concentrations (1 μM, 10 μM and 100 μM) were applied to the neurons and after 15 minutes of rifampicin addition, neurons were laser axotomized. Viability of the cells was evaluated by propidium iodide staining after 24 hours of axotomy. Results: Laser axotomy decreases the cortical neuron viability significantly by 80.45%, while rifampicin pre-treatment increases their viability in all three dosages in a statistically significant manner. Conclusion: Rifampicin has an acute neuroprotective effect on the viability of the laser axotomized cortical neurons.
    Keywords laser axotomy ; rifampicin ; neuronal viability ; primary cortical neuron ; neurotrauma ; lazer aksotomi ; rifampisin ; nöronal canlılık ; primer kortikal nöron ; nörotravma ; Medicine ; R
    Language English
    Publishing date 2019-08-01T00:00:00Z
    Publisher Alanya Alaaddin Keykubat University
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: Effects of Tumor Necrosis Factor Alpha Blocker Adalimumab in Experimental Brain Injury

    Mehmet Yalçın Günal / Seyda Cankaya / Sukru Burak Tonuk / Ekrem Musa Ozdemi̇r / Ayse Arzu Sayın Sakul

    Acta Medica Alanya, Vol 3, Iss 3, Pp 306-

    2019  Volume 310

    Abstract: Aim: We aimed to investigate the neuroprotective role of adalimumab based on the hypothesis that "TNF-alpha inhibitor Adalimumab may affect inflammation-related neuronal injury due to its anti-inflammatory effect". Methods: To investigate the effects of ... ...

    Abstract Aim: We aimed to investigate the neuroprotective role of adalimumab based on the hypothesis that "TNF-alpha inhibitor Adalimumab may affect inflammation-related neuronal injury due to its anti-inflammatory effect". Methods: To investigate the effects of Adalimumab, we induced brain injury in mice using a cold trauma model and evaluated the underlying cell survival/ death mechanisms via cresyl violet and calculated infarct/edema volume with image analyze system. Results: Although our data indicated a tendency to decreased infarct and edema volume, these findings are not significant statistically. Conclusion: To the best of our knowledge, this is the first study evaluating the neuroprotective effect of Adalimumab on injured neurons.
    Keywords beyin hasarı ; adalimumab ; nöroprotektif etki ; brain injury ; neural protection ; Medicine ; R
    Language English
    Publishing date 2019-10-01T00:00:00Z
    Publisher Alanya Alaaddin Keykubat University
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients

    Burak Yulug / Ozlem Altay / Xiangyu Li / Lutfu Hanoglu / Seyda Cankaya / Simon Lam / Halil Aziz Velioglu / Hong Yang / Ebru Coskun / Ezgi Idil / Rahim Nogaylar / Ahmet Ozsimsek / Cemil Bayram / Ismail Bolat / Sena Oner / Ozlem Ozdemir Tozlu / Mehmet Enes Arslan / Ahmet Hacimuftuoglu / Serkan Yildirim /
    Muhammad Arif / Saeed Shoaie / Cheng Zhang / Jens Nielsen / Hasan Turkez / Jan Borén / Mathias Uhlén / Adil Mardinoglu

    Translational Neurodegeneration, Vol 12, Iss 1, Pp 1-

    a randomised, double-blinded, placebo-controlled phase-II trial

    2023  Volume 23

    Abstract: Abstract Background Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined metabolic activators (CMA) to the AD rat model and observed that CMA improves the ... ...

    Abstract Abstract Background Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined metabolic activators (CMA) to the AD rat model and observed that CMA improves the AD-associated histological parameters in the animals. CMA promotes mitochondrial fatty acid uptake from the cytosol, facilitates fatty acid oxidation in the mitochondria, and alleviates oxidative stress. Methods Here, we designed a randomised, double-blinded, placebo-controlled phase-II clinical trial and studied the effect of CMA administration on the global metabolism of AD patients. One-dose CMA included 12.35 g L-serine (61.75%), 1 g nicotinamide riboside (5%), 2.55 g N-acetyl-L-cysteine (12.75%), and 3.73 g L-carnitine tartrate (18.65%). AD patients received one dose of CMA or placebo daily during the first 28 days and twice daily between day 28 and day 84. The primary endpoint was the difference in the cognitive function and daily living activity scores between the placebo and the treatment arms. The secondary aim of this study was to evaluate the safety and tolerability of CMA. A comprehensive plasma metabolome and proteome analysis was also performed to evaluate the efficacy of the CMA in AD patients. Results We showed a significant decrease of AD Assessment Scale-cognitive subscale (ADAS-Cog) score on day 84 vs day 0 (P = 0.00001, 29% improvement) in the CMA group. Moreover, there was a significant decline (P = 0.0073) in ADAS-Cog scores (improvement of cognitive functions) in the CMA compared to the placebo group in patients with higher ADAS-Cog scores. Improved cognitive functions in AD patients were supported by the relevant alterations in the hippocampal volumes and cortical thickness based on imaging analysis. Moreover, the plasma levels of proteins and metabolites associated with NAD + and glutathione metabolism were significantly improved after CMA treatment. Conclusion Our results indicate that treatment of AD patients with CMA can lead to ...
    Keywords Alzheimer’s disease ; Combined metabolic activators ; Multi-omics ; Systems biology ; Systems medicine ; Neurology. Diseases of the nervous system ; RC346-429
    Subject code 610
    Language English
    Publishing date 2023-01-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top